Medical

Canadian respiratory drug developer Asmacure has dosed the first subjects in a Phase 1/2 clinical trial of its ASM-024 inhalation powder for the treatment of asthma, the company says. According to the company, “ASM-024 has… Read more . . .

According to Activaero, a Phase 2 trial of a budesonide suspension delivered using its FAVORITE (Flow and Volume Controlled Inhalation Technology) system in children with mild to moderate asthma improved asthma control, reduced treatment times,… Read more . . .

According to AstraZeneca, data from the PATHOS real world study show fewer exacerbations and fewer hospitalizations for COPD patients treated with the Symbicort Turbuhaler than for those treated with Seretide (Advair). The study was published… Read more . . .

Acorda Therapeutics presented data from a Phase 1 study of its diazepam nasal spray at the American Academy of Neurology Annual Meeting this week showing that the plasma bioavailability of a 20 mg dose of… Read more . . .

Upsher Smith presented positive Phase 1 data for its USL261 intranasal midazolam at the American Academy of Neurology (AAN) Meeting this week. The company launched a website to recruit patients for a Phase 3 study… Read more . . .

The first issue of the Lancet Respiratory Medicine journal is now available online and in print. Volume 1, Issue 1 includes articles on the efficacy of ICS/LABA combination inhalers and on the appropriateness of GOLD… Read more . . .

A study published February 27, 2013 in PLOS ONE found that patients using the Asthmapolis remote inhaler monitoring system who received weekly email reports on their inhaler usage experienced significant reduction in symptoms and reported… Read more . . .

According to Critical Pharmaceuticals, a Phase 1b study has shown that its CP024 dry powder intranasal human growth hormone (hGH) was well tolerated with only a few minor adverse effects and showed a linear dose… Read more . . .

California-based NEONC Technologies has announced plans for clinical trials of its NEO100 intranasal formulation of monoterpene perillyl alcohol (POH) for the treatment of gliomas and other CNS cancers. NEONC Chairman and CEO Thomas Chen, who… Read more . . .